Stockscreener 앱 받기
0.85
1.99%
-0.0097
전일 마감가:
$0.8597
열려 있는:
$0.84
하루 거래량:
37,939
Relative Volume:
0.08
시가총액:
$49.85M
수익:
$2.43M
순이익/손실:
$-52.67M
주가수익비율:
-0.6746
EPS:
-1.26
순현금흐름:
$-33.04M
1주 성능:
+2.76%
1개월 성능:
+6.83%
6개월 성능:
-0.11%
1년 성능:
-41.89%
1일 변동 폭
$0.8292
$0.8597
1주일 범위
$0.82
$0.9094
52주 변동 폭
$0.6301
$1.58
Lucid Diagnostics Inc Stock (LUCD) Company Profile
명칭
Lucid Diagnostics Inc
전화
212 949 4319
주소
360 MADISON AVENUE, NEW YORK
LUCD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.8426 | 49.85M | 2.43M | -52.67M | -33.04M | -1.26 |
|
ABT
Abbott Laboratories
|
112.48 | 196.55B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.53 | 141.03B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
366.24 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
81.34 | 104.60B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
73.26 | 43.28B | 6.60B | 4.16B | 490.10M | 6.93 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-11-08 | 개시 | BTIG Research | Buy |
| 2021-11-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Needham | Buy |
Lucid Diagnostics Inc 주식(LUCD)의 최신 뉴스
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald
Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com
Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Quantisnow
Lucid Diagnostics Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Defense World
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online
Lucid Diagnostics Partners with VITALExam to Screen Firefighters at High Risk of Esophageal Cancer - StockTitan
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online
Lucid Diagnostics' SWOT analysis: stock faces challenges amid market potential - Investing.com
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - Morningstar
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt
Lucid Diagnostics' EsoGuard Shows Breakthrough 85% Compliance Rate in Major Clinical Study - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $7.00 at Ascendiant Capital Markets - Defense World
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - The Eastern Progress Online
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones – Company AnnouncementFT.com - Financial Times
Lucid Diagnostics Secures $21.95M Convertible Note Financing, Extends Cash Runway - StockTitan
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 30.6% in November - MarketBeat
Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements - TipRanks
Head-To-Head Review: Lucid Diagnostics (NASDAQ:LUCD) & DIH Holding US (NASDAQ:DHAI) - Defense World
This Pill-Size Diagnostic Seeks to Prevent Thousands of Esophageal Cancer Deaths - MedCity News
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com
Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com
Lucid Diagnostics' SWOT analysis: stock outlook amid reimbursement progress - Investing.com
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - Morningstar
Lucid Diagnostics Announces Agreement for Sale of Senior Secured Convertible Notes - Defense World
Lucid Diagnostics Inc. announced that it expects to receive $21.75 million in funding - Marketscreener.com
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com
Cantor Fitzgerald cuts Lucid Diagnostics stock target, overweight on challenges - Investing.com Australia
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald - MarketBeat
PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy
Lucid Diagnostics (NASDAQ:LUCD) Provides Business Update and Financial Results - Defense World
Lucid Diagnostics' (LUCD) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat
PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Lucid Diagnostics reports revenue growth and strategic expansion - Investing.com UK
PAVmed Hits Record $1.2M EsoGuard Revenue in Q3, Up 20% Despite Cash Challenges - StockTitan
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Lucid Diagnostics Reports Q3 Revenue Growth and Strategic Expansion - TipRanks
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
Needham maintains Buy rating on Lucid Diagnostics shares - Investing.com
Needham maintains Buy rating on Lucid Diagnostics shares By Investing.com - Investing.com UK
Lucid Diagnostics Reports Revenue Growth and Secures Funding - TipRanks
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire
Lucid Diagnostics Announces Convertible Notes Exchange Initiative - TipRanks
Lucid Diagnostics (LUCD) Scheduled to Post Earnings on Wednesday - MarketBeat
Lucid Diagnostics Inc (LUCD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.55%
0.60%
자본화:
|
볼륨(24시간):